Non-Pharmacological Treatment of Peripheral Vascular Disease

  • Janice TsuiEmail author
  • George Hamilton


Peripheral vascular disease (PVD) is a significant healthcare issue in the West and its management remains challenging. The prognosis of patients with PVD is poor in terms of cardiovascular morbidity and mortality, and in patients with advanced disease, there is significant risk of limb loss. Treatment aims are to reduce cardiovascular risk, manage symptoms, and prevent limb loss. This chapter gives an overview of the non-pharmacological treatments available for the management of PVD, with a focus on critical limb ischemia.


Peripheral Vascular Disease Limb Salvage Spinal Cord Stimulation Critical Limb Ischemia Intermittent Claudication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20:384–92.PubMedCrossRefGoogle Scholar
  2. 2.
    Hooi JD, Kester AD, Stoffers HE, Overdijk MM, van Ree JW, Knottnerus JA. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am J Epidemiol. 2001;153:666–72.PubMedCrossRefGoogle Scholar
  3. 3.
    Critical limb ischaemia: management and outcome. Report of a national survey. The Vascular Surgical Society of Great Britain and Ireland. Eur J Vasc Endovasc Surg. 1995;10:108–13.Google Scholar
  4. 4.
    Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med. 1997;2:221–6.PubMedGoogle Scholar
  5. 5.
    Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996;25:1172–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Bianchi C, Montalvo V, Ou HW, Bishop V, Abou-Zamzam Jr AM. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation. Ann Vasc Surg. 2007;21:163–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Khan S, Flather M, Mister R, Delahunty N, Fowkes G, Bradbury A, et al. Characteristics and treatments of patients with peripheral arterial disease referred to UK vascular clinics: results of a prospective registry. Eur J Vasc Endovasc Surg. 2007;33:442–50.PubMedCrossRefGoogle Scholar
  9. 9.
    Zeymer U, Parhofer KG, Pittrow D, Binz C, Schwertfeger M, Limbourg T, et al. Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort. Clin Res Cardiol. 2009;98:249–56.PubMedCrossRefGoogle Scholar
  10. 10.
    Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg. 1996;23:104–15.PubMedCrossRefGoogle Scholar
  11. 11.
    Gardner AW, Katzel LI, Sorkin JD, Bradham DD, Hochberg MC, Flinn WR, et al. Exercise rehabilitation improves functional outcomes and peripheral circulation in patients with intermittent claudication: a randomized controlled trial. J Am Geriatr Soc. 2001;49:755–62.PubMedCrossRefGoogle Scholar
  12. 12.
    Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463–654.PubMedCrossRefGoogle Scholar
  13. 13.
    Varty K, Nydahl S, Butterworth P, Errington M, Bolia A, Bell PR, et al. Changes in the management of critical limb ischaemia. Br J Surg. 1996;83:953–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Forbes JF, Adam DJ, Bell J, Fowkes FG, Gillespie I, Raab GM, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis. J Vasc Surg. 2010;51(5 Suppl):43S–51.PubMedCrossRefGoogle Scholar
  15. 15.
    Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FG, Gillespie I, et al. Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial. Health Technol Assess. 2010;14:1–210, i–iv.Google Scholar
  16. 16.
    Timaran CH, Stevens SL, Freeman MB, Goldman MH. Predictors for adverse outcome after iliac angioplasty and stenting for limb-threatening ischemia. J Vasc Surg. 2002;36(3):507–13.PubMedCrossRefGoogle Scholar
  17. 17.
    Tisi PV, Mirnezami A, Baker S, Tawn J, Parvin SD, Darke SG. Role of subintimal angioplasty in the treatment of chronic lower limb ischaemia. Eur J Vasc Endovasc Surg. 2002;24:417–22.PubMedCrossRefGoogle Scholar
  18. 18.
    Myers SI, Myers DJ, Ahmend A, Ramakrishnan V. Preliminary results of subintimal angioplasty for limb salvage in lower extremities with severe chronic ischemia and limb-threatening ischemia. J Vasc Surg. 2006;44:1239–46.PubMedCrossRefGoogle Scholar
  19. 19.
    Conrad MF, Cambria RP, Stone DH, Brewster DC, Kwolek CJ, Watkins MT, et al. Intermediate results of percutaneous endovascular therapy of femoropopliteal occlusive disease: a contemporary series. J Vasc Surg. 2006;44:762–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Muradin GS, Bosch JL, Stijnen T, Hunink MG. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology. 2001;221:137–45.PubMedCrossRefGoogle Scholar
  21. 21.
    Dorros G, Lewin RF, Jamnadas P, Mathiak LM. Below-the-knee angioplasty: tibioperoneal vessels, the acute outcome. Cathet Cardiovasc Diagn. 1990;19:170–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Dorros G, Jaff MR, Dorros AM, Mathiak LM, He T. Tibioperoneal (outflow lesion) angioplasty can be used as primary treatment in 235 patients with critical limb ischemia: five-year follow-up. Circulation. 2001;104:2057–62.PubMedCrossRefGoogle Scholar
  23. 23.
    Feiring AJ, Wesolowski AA, Lade S. Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication: early and one-year outcomes. J Am Coll Cardiol. 2004;44:2307–14.PubMedCrossRefGoogle Scholar
  24. 24.
    Commeau P, Barragan P, Roquebert PO. Sirolimus for below the knee lesions: mid-term results of SiroBTK study. Catheter Cardiovasc Interv. 2006;68:793–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Gandini R, Pipitone V, Stefanini M, Maresca L, Spinelli A, Colangelo V, et al. The “Safari” technique to perform difficult subintimal infragenicular vessels. Cardiovasc Intervent Radiol. 2007;30:469–73.PubMedCrossRefGoogle Scholar
  26. 26.
    Arain SA, White CJ. Endovascular therapy for critical limb ischemia. Vasc Med. 2008;13:267–79.PubMedCrossRefGoogle Scholar
  27. 27.
    Axisa B, Fishwick G, Bolia A, Thompson MM, London NJ, Bell PR, et al. Complications following peripheral angioplasty. Ann R Coll Surg Engl. 2002;84:39–42.PubMedGoogle Scholar
  28. 28.
    Belli AM, Cumberland DC, Knox AM, Procter AE, Welsh CL. The complication rate of percutaneous peripheral balloon angioplasty. Clin Radiol. 1990;41:380–3.PubMedCrossRefGoogle Scholar
  29. 29.
    Vlachou PA, Karkos CD, Bains S, McCarthy MJ, Fishwick G, Bolia A. Percutaneous ultrasound-guided thrombin injection for the treatment of iatrogenic femoral artery pseudoaneurysms. Eur J Radiol. 2011;77:172–4.PubMedCrossRefGoogle Scholar
  30. 30.
    de Vries SO, Hunink MG. Results of aortic bifurcation grafts for aortoiliac occlusive disease: a meta-analysis. J Vasc Surg. 1997;26:558–69.PubMedCrossRefGoogle Scholar
  31. 31.
    McDaniel MD, Macdonald PD, Haver RA, Littenberg B. Published results of surgery for aortoiliac occlusive disease. Ann Vasc Surg. 1997;11:425–41.PubMedCrossRefGoogle Scholar
  32. 32.
    Desai M, Tsui J, Davis M, Myint F, Wilson A, Baker DM, et al. Isolated endarterectomy of femoral bifurcation in critical limb ischemia: is restoration of inline flow essential? Angiology. 2011;62:119–25.PubMedCrossRefGoogle Scholar
  33. 33.
    Hunink MG, Wong JB, Donaldson MC, Meyerovitz MF, Harrington DP. Patency results of percutaneous and surgical revascularization for femoropopliteal arterial disease. Med Decis Making. 1994;14:71–81.PubMedCrossRefGoogle Scholar
  34. 34.
    Tsui JC, Dashwood MR. Recent strategies to reduce vein graft occlusion: a need to limit the effect of vascular damage. Eur J Vasc Endovasc Surg. 2002;23(3):202–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Stonebridge PA, Prescott RJ, Ruckley CV. Randomized trial comparing infrainguinal polytetrafluoroethylene bypass grafting with and without vein interposition cuff at the distal anastomosis. The Joint Vascular Research Group. J Vasc Surg. 1997;26:543–50.PubMedCrossRefGoogle Scholar
  36. 36.
    Hamsho A, Nott D, Harris PL. Prospective randomised trial of distal arteriovenous fistula as an adjunct to femoro-infrapopliteal PTFE bypass. Eur J Vasc Endovasc Surg. 1999;17:197–201.PubMedCrossRefGoogle Scholar
  37. 37.
    Ravi S, Chaikof EL. Biomaterials for vascular tissue engineering. Regen Med. 2010;5:107–20.PubMedCrossRefGoogle Scholar
  38. 38.
    de Mel A, Bolvin C, Edirisinghe M, Hamilton G, Seifalian AM. Development of cardiovascular bypass grafts: endothelialization and applications of nanotechnology. Expert Rev Cardiovasc Ther. 2008;6:1259–77.PubMedCrossRefGoogle Scholar
  39. 39.
    Melliere D, Cron J, Allaire E, Desgranges P, Becquemin JP. Indications and benefits of simultaneous endoluminal balloon angioplasty and open surgery during elective lower limb revascularization. Cardiovasc Surg. 1999;7:242–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Miyahara T, Miyata T, Shigematsu H, Shigematsu K, Okamoto H, Nakazawa T, et al. Long-term results of combined iliac endovascular intervention and infrainguinal surgical revascularization for treatment of multilevel arterial occlusive disease. Int Angiol. 2005;24:340–8.PubMedGoogle Scholar
  41. 41.
    Dougherty MJ, Young LP, Calligaro KD. One hundred twenty-five concomitant endovascular and open procedures for lower extremity arterial disease. J Vasc Surg. 2003;37:316–22.PubMedCrossRefGoogle Scholar
  42. 42.
    Pieri S, Agresti P, Ialongo P, Fedeli S, Di Cesare F, Ricci G. Lumbar sympathectomy under CT guidance: therapeutic option in critical limb ischaemia. Radiol Med. 2005;109:430–7.PubMedGoogle Scholar
  43. 43.
    Nemes R, Surlin V, Chiutu L, Georgescu E, Georgescu M, Georgescu I. Retroperitoneoscopic lumbar sympathectomy: prospective study upon a series of 50 consecutive patients. Surg Endosc 2011, Surg Endosc 2011;25:3066–70.Google Scholar
  44. 44.
    Holiday FA, Barendregt WB, Slappendel R, Crul BJ, Buskens FG, van der Vliet JA. Lumbar sympathectomy in critical limb ischaemia: surgical, chemical or not at all? Cardiovasc Surg. 1999;7:200–2.PubMedCrossRefGoogle Scholar
  45. 45.
    Jivegard LE, Augustinsson LE, Holm J, Risberg B, Ortenwall P. Effects of spinal cord stimulation (SCS) in patients with inoperable severe lower limb ischaemia: a prospective randomised controlled study. Eur J Vasc Endovasc Surg. 1995;9:421–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Klomp HM, Spincemaille GH, Steyerberg EW, Habbema JD, Van Urk H. Spinal-cord stimulation in critical limb ischaemia: a randomised trial. ESES Study Group. Lancet. 1999;353:1040–4.PubMedCrossRefGoogle Scholar
  47. 47.
    Klomp HM, Steyerberg EW, Habbema JD, Van Urk H. What is the evidence on efficacy of spinal cord stimulation in (subgroups of) patients with critical limb ischemia? Ann Vasc Surg. 2009;23:355–63.PubMedCrossRefGoogle Scholar
  48. 48.
    Klomp HM, Steyerberg EW, Van Urk H, Habbema JD. Spinal cord stimulation is not cost-effective for non-surgical management of critical limb ischaemia. Eur J Vasc Endovasc Surg. 2006;31:500–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 1999;103:1231–6.PubMedCrossRefGoogle Scholar
  50. 50.
    De Haro J, Acin F, Lopez-Quintana A, Florez A, Martinez-Aguilar E, Varela C. Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease. Heart Vessels. 2009;24:321–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002;359:2053–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360:427–35.PubMedCrossRefGoogle Scholar
  53. 53.
    Haitt WR, Baumgartner I, Nikol S, Van Belle E, Driver V, Norgren L, et al. NV1FGF gene therapy on amputation-free survival in critical limb ischaemia – phase 3 randomised double-blind placebo controlled trial (TAMARIS). Circulation. 2010;122:2217.Google Scholar
  54. 54.
    Information Services Division NHS Scotland on behalf of National Amputee Statistical Database for the UK (NASDAB). The Amputee Statistical Database for UK Annual Report 2006/2007.
  55. 55.
    Kaplow M, Muroff F, Fish W, Stillwell D, Mitchell N. The dysvascular amputee: multidisciplinary management. Can J Surg. 1983;26:368–9.PubMedGoogle Scholar
  56. 56.
    Hakimi KN. Pre-operative rehabilitation evaluation of the dysvascular patient prior to amputation. Phys Med Rehabil Clin N Am. 2009;20:677–88.PubMedCrossRefGoogle Scholar
  57. 57.
    Adam DJ, Bradbury AW. TASC II document on the management of peripheral arterial disease. Eur J Vasc Endovasc Surg. 2007;33:1–2.PubMedCrossRefGoogle Scholar
  58. 58.
    Dormandy J, Heeck L, Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg. 1999;12:142–7.PubMedGoogle Scholar
  59. 59.
    Ebskov LB, Schroeder TV, Holstein PE. Epidemiology of leg amputation: the influence of vascular surgery. Br J Surg. 1994;81:1600–3.PubMedCrossRefGoogle Scholar
  60. 60.
    Luther M. The influence of arterial reconstructive surgery on the outcome of critical leg ischaemia. Eur J Vasc Surg. 1994;8:682–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Dormandy J, Heeck L, Vig S. Major amputations: clinical patterns and predictors. Semin Vasc Surg. 1999;12:154–61.PubMedGoogle Scholar
  62. 62.
    Dillingham TR, Pezzin LE, Shore AD. Reamputation, mortality, and health care costs among persons with dysvascular lower-limb amputations. Arch Phys Med Rehabil. 2005;86:480–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2012

Authors and Affiliations

  1. 1.Royal Free Vascular UnitRoyal Free Hampstead NHS TrustLondonUK

Personalised recommendations